Sunday, December 3, 2023
WebMD Global requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships with ineligible companies.
Disclosures for additional planners can be found here.
Professor, Sydney Medical School, University of Sydney
Head, Gene and Stem Cell Therapy Program
Centenary Institute
Head of Department, Cell and Molecular Therapies
Royal Prince Alfred Hospital
President, International Society for Cell and Gene Therapy
Sydney, Australia
Professor of Pediatrics
Perelman School of Medicine
Chief, Division of Hematology
Children’s Hospital of Philadelphia
University of Pennsylvania
Philadelphia, Pennsylvania, United States
This activity has been peer reviewed and the reviewer has no relevant financial relationships.
Posted: 12/28/2022
This educational activity is intended for an international audience of non-US pediatricians, hematology/oncology specialists, and transplant surgeons.
The goal of this activity is for learners to be better able to increase familiarity with gene therapies for hematological conditions.
Upon completion of this activity, participants will:
